In this article, Caidya’s Executive Chairman, Lingshi Tan will examine evolving models in translational medicine (especially in China) and their implications for early-stage clinical development. As scientific innovation accelerates and development pathways grow increasingly complex, it is essential that sponsors adopt rigorous, strategically aligned approaches to proof-of-concept, regulatory engagement, and data integration.
Read the full article here
Back to Resource Center